Against the common association of voyages of exploration with discovery and the arrival of modernity, this essay argues that maintenance and repair were essential to the success of such voyages and that maintenance and innovation are best seen as fundamentally integrated. Using the Russian circumnavigatory voyage of Adam von Krusenstern and Urey Lisianskii in 1803-7 as a case study, the essay explores the diverse forms and roles of infrastructure and repair work in enabling a voyage of exploration, and reveals the tensions and debates that considerations of maintenance evoked among ships' officers, crews, and the peoples they encountered.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464720 | PMC |
| http://dx.doi.org/10.1177/00732753211060186 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The study investigates the safety, tolerability, and pharmacokinetics of BIIB078, an investigational treatment targeting the genetic cause of amyotrophic lateral sclerosis (ALS) linked to the C9orf72 gene mutation.
- The trial involved 106 participants with C9orf72-associated ALS, who were randomly assigned to receive varying doses of BIIB078 or a placebo over a treatment period of three to six months.
- Results showed that all participants experienced at least one adverse event, mostly mild or moderate, indicating that while BIIB078 did pose some risks, it did not lead to a high rate of treatment discontinuation.
Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository.
Blood Adv
July 2024
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Clonal hematopoiesis (CH) is an age-associated phenomenon leading to an increased risk of both hematologic malignancy and nonmalignant organ dysfunction. Increasingly available genetic testing has made the incidental discovery of CH clinically common yet evidence-based guidelines and effective management strategies to prevent adverse CH health outcomes are lacking. To address this gap, the prospective CHIVE (clonal hematopoiesis and inflammation in the vasculature) registry and biorepository was created to identify and monitor individuals at risk, support multidisciplinary CH clinics, and refine taxonomy and standards of practice for CH risk mitigation.
View Article and Find Full Text PDFSafety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Neurol Ther
June 2024
Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Introduction: Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia (TD) and chorea associated with Huntington disease (HD). To enhance detection of safety signals across individual trials, integrated safety analyses of deutetrabenazine in TD and HD chorea were conducted.
Methods: For TD, safety data were integrated from two 12-week pivotal studies (ARM-TD and AIM-TD) and through week 15 of the open-label extension (OLE) study (RIM-TD).
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.
Clin Park Relat Disord
February 2024
Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, KS, USA.
Background: As Parkinson's disease (PD) advances, management is challenged by an increasingly variable and inconsistent response to oral dopaminergic therapy, requiring special considerations by the provider. Continuous 24 h/day subcutaneous infusion of foslevodopa/foscarbidopa (LDp/CDp) provides steady dopaminergic stimulation that can reduce symptom fluctuation.
Objective: Our aim is to review the initiation, optimization, and maintenance of LDp/CDp therapy, identify possible challenges, and share potential mitigations.
Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
Dermatol Ther (Heidelb)
November 2023
Department of Dermatology, National Taiwan University Hospital, No. 7, Chung-Shan S. Road, Taipei, 100, Taiwan.
Introduction: Guselkumab is a human monoclonal antibody against IL-23 used in the treatment of moderate-to-severe psoriasis. This post-hoc analysis evaluated the efficacy and safety of guselkumab in the Asian subpopulation of VOYAGE 1 and VOYAGE 2 through 5 years.
Methods: The proportions of guselkumab-treated Asian patients (VOYAGE 1 and 2) achieving Psoriasis Area and Severity Index (PASI) 90 and PASI 100, Investigator's Global Assessment (IGA) scores of 0/1 and 0, and Dermatology Life Quality Index (DLQI) scores of 0/1 (week 100 through week 252) were assessed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!